Form 8-K - Current report:
SEC Accession No. 0001193125-24-253174
Filing Date
2024-11-07
Accepted
2024-11-07 16:29:54
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d862473d8k.htm   iXBRL 8-K 23550
2 EX-99.1 d862473dex991.htm EX-99.1 60074
6 GRAPHIC g862473g1108005806784.jpg GRAPHIC 4480
  Complete submission text file 0001193125-24-253174.txt   220348

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aclx-20241107.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aclx-20241107_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aclx-20241107_pre.xml EX-101.PRE 10804
17 EXTRACTED XBRL INSTANCE DOCUMENT d862473d8k_htm.xml XML 3494
Mailing Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065
Business Address 800 BRIDGE PARKWAY REDWOOD CITY CA 94065 240-327-0603
Arcellx, Inc. (Filer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41259 | Film No.: 241436317
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)